Drugs / CC-91633
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04951778 | Dec 2021 → Jul 2025 | acute myeloid leukemia, myelodysplastic syndrome | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-91633 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04951778 ↗ |
| Route | Oral | “Administered orally according to the assigned treatment schedule” NCT04951778 ↗ |